Corinne Johnson
Stock Analyst at Goldman Sachs
(3.76)
# 1,925
Out of 4,382 analysts
240
Total ratings
51%
Success rate
6%
Average return
Main Sectors:
Stocks Rated by Corinne Johnson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TGTX TG Therapeutics | Maintained: Hold | $41 | $40.16 | +2.09% | 21 | Jun 3, 2026 | |
| SNDX Syndax Pharmaceuticals | Maintained: Buy | $34 | $17.34 | +96.08% | 7 | Jun 3, 2026 | |
| IDYA IDEAYA Biosciences | Maintained: Hold | $35 → $36 | $28.29 | +27.25% | 11 | Jun 3, 2026 | |
| NBIX Neurocrine Biosciences | Initiated Coverage: Buy | $182 → $213 | $163.88 | +29.97% | 3 | Jun 2, 2026 | |
| ORIC ORIC Pharmaceuticals | Reiterated: Buy | $15 | $7.50 | +100.00% | 2 | Jun 2, 2026 | |
| BHVN Biohaven | Maintained: Buy | $27 → $25 | $10.80 | +131.48% | 3 | May 28, 2026 | |
| ALT Altimmune | Upgraded: Hold | $2.5 | $2.71 | -7.75% | 8 | Apr 24, 2026 | |
| RYTM Rhythm Pharmaceuticals | Maintained: Buy | $158 | $86.40 | +82.87% | 30 | Apr 15, 2026 | |
| IMVT Immunovant | Rated: Hold | $28 → $32 | $31.11 | +2.86% | 6 | Apr 15, 2026 | |
| ROIV Roivant Sciences | Maintained: Buy | $38 → $41 | $28.58 | +43.46% | 29 | Apr 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $102 → $101 | $37.58 | +168.76% | 2 | Mar 16, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Sell | $1 | $1.17 | -14.53% | 17 | Feb 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $56 → $82 | $53.72 | +52.64% | 6 | Jan 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Sell | $56 | $71.53 | -21.71% | 17 | Dec 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Sell | $32 | $30.28 | +5.58% | 1 | Dec 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $10 → $20 | $13.32 | +50.15% | 18 | Sep 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $30.35 | - | 3 | Jul 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | $28 → $33 | $32.20 | +2.48% | 22 | Jul 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $3.69 | n/a | 4 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Sell | n/a | $1.64 | n/a | 5 | Jul 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $8.21 | n/a | 6 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $1.11 | n/a | 14 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $4.36 | n/a | 4 | Aug 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $22 | $2.20 | n/a | 1 | Sep 14, 2021 |
TG Therapeutics
Jun 3, 2026
Maintained: Hold
Price Target: $41
Current: $40.16
Upside: +2.09%
Syndax Pharmaceuticals
Jun 3, 2026
Maintained: Buy
Price Target: $34
Current: $17.34
Upside: +96.08%
IDEAYA Biosciences
Jun 3, 2026
Maintained: Hold
Price Target: $35 → $36
Current: $28.29
Upside: +27.25%
Neurocrine Biosciences
Jun 2, 2026
Initiated Coverage: Buy
Price Target: $182 → $213
Current: $163.88
Upside: +29.97%
ORIC Pharmaceuticals
Jun 2, 2026
Reiterated: Buy
Price Target: $15
Current: $7.50
Upside: +100.00%
Biohaven
May 28, 2026
Maintained: Buy
Price Target: $27 → $25
Current: $10.80
Upside: +131.48%
Altimmune
Apr 24, 2026
Upgraded: Hold
Price Target: $2.5
Current: $2.71
Upside: -7.75%
Rhythm Pharmaceuticals
Apr 15, 2026
Maintained: Buy
Price Target: $158
Current: $86.40
Upside: +82.87%
Immunovant
Apr 15, 2026
Rated: Hold
Price Target: $28 → $32
Current: $31.11
Upside: +2.86%
Roivant Sciences
Apr 15, 2026
Maintained: Buy
Price Target: $38 → $41
Current: $28.58
Upside: +43.46%
Mar 16, 2026
Maintained: Buy
Price Target: $102 → $101
Current: $37.58
Upside: +168.76%
Feb 25, 2026
Reiterated: Sell
Price Target: $1
Current: $1.17
Upside: -14.53%
Jan 12, 2026
Maintained: Buy
Price Target: $56 → $82
Current: $53.72
Upside: +52.64%
Dec 4, 2025
Downgraded: Sell
Price Target: $56
Current: $71.53
Upside: -21.71%
Dec 4, 2025
Initiated Coverage: Sell
Price Target: $32
Current: $30.28
Upside: +5.58%
Sep 16, 2025
Maintained: Buy
Price Target: $10 → $20
Current: $13.32
Upside: +50.15%
Jul 18, 2025
Maintained: Buy
Price Target: n/a
Current: $30.35
Upside: -
Jul 10, 2025
Initiated Coverage: Hold
Price Target: $28 → $33
Current: $32.20
Upside: +2.48%
Jul 31, 2024
Maintained: Buy
Price Target: n/a
Current: $3.69
Upside: n/a
Jul 24, 2024
Reiterated: Sell
Price Target: n/a
Current: $1.64
Upside: n/a
Jun 18, 2024
Maintained: Hold
Price Target: n/a
Current: $8.21
Upside: n/a
Nov 14, 2023
Reiterated: Hold
Price Target: n/a
Current: $1.11
Upside: n/a
Aug 7, 2023
Reiterated: Buy
Price Target: n/a
Current: $4.36
Upside: n/a
Sep 14, 2021
Downgraded: Hold
Price Target: $22
Current: $2.20
Upside: n/a